Evogene Ltd Ord (EVGN) Stock Price, Quote & News

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 931 1900

Fax: 972 8 946 6724

Website: www.evogene.com

Address:

13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel

dukenuke Aug. 21 at 9:07 PM

$EVGN well, seems like the only thing to hang on to hear is the potential of a Keytruda partnership that would allow them to own the most effective version, if the Biomica candidate works. When Keytrudy becomes generic, i suppose that would open up other partnerships to do the same with, i believe the most profitable drug on the maeket. Long shot but big if true

2 · Reply

gekkooo Aug. 20 at 7:57 AM

$EVGN where is the sec? https://www.linkedin.com/posts/evogene_financialresults-biotechnology-lifesciences-activity-7363531848372703233-bdJO/ Early stage discussions are currently underway to evaluate potential partnerships opportunities. It is important to highlight that additional funding is necessary to advance to Phase II of the clinical study. Meanwhile, Biomica established an expense reduction plan, which will be completed by the third quarter of 2025. This reduction in expenses is already reflected in Biomica's financial results of the first quarter of 2025. https://seekingalpha.com/article/4788946-evogene-ltd-evgn-q1-2025-earnings-call-transcript Biomica is now focused on two key goals: completion of its clinical trial expected in early 2026 https://seekingalpha.com/article/4814901-evogene-ltd-evgn-q2-2025-earnings-call-transcript

0 · Reply

WilliamAnastasiades488 Aug. 18 at 2:46 PM

$EVGN is working on unique biotech applications, but progress is slow. KLTO’s ability to fast-track with AAVone looks like a smarter approach.

0 · Reply

mangingriskandcandles Aug. 5 at 8:27 PM

$EVGN I am ready for it to go up another 100%

0 · Reply

dukenuke Aug. 5 at 7:50 PM

$EVGN well this is highly unusual

0 · Reply

omenkes Jul. 30 at 11:37 AM

$EVGN la vie bio needed money as their partnership with corteva was terminated and those bio fungicides were supposed to be the cash flow of la vie bio. Biomica represents a phase 1 that will finish later this year with results and it was designed to help an existing cancer drug work better for certain cancers. will be interesting over the next 12 months. casterra is a case of a company that needs to mature towards being sold.

1 · Reply

dukenuke Jul. 29 at 3:11 PM

$EVGN Casterra new website: https://casterra.co/

1 · Reply

SmartBetting Jul. 24 at 12:19 PM

$EVGN goodluck.

0 · Reply

watcher64 Jul. 19 at 1:38 PM

$EVGN Gonna start adding more of this on Monday. At this price, the upside far outstrips the risk.

1 · Reply

dukenuke Jul. 16 at 2:43 AM

$EVGN anybody heard anything from Casterra lately? They seem to have gone dark.

1 · Reply

Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 7:00 AM EDT - 4 days ago

Evogene Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 7:00 AM EDT - 11 days ago

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Jul 29, 2025, 7:00 AM EDT - 25 days ago

Evogene Schedules Second Quarter 2025 Financial Results Release

Jul 8, 2025, 7:00 AM EDT - 6 weeks ago

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

ICL

Jun 10, 2025, 7:00 AM EDT - 2 months ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

May 21, 2025, 2:08 PM EDT - 3 months ago

Evogene Ltd. (EVGN) Q1 2025 Earnings Call Transcript

May 21, 2025, 7:00 AM EDT - 3 months ago

Evogene Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 3 months ago

Evogene Schedules First Quarter 2025 Financial Results Release

Apr 21, 2025, 7:00 AM EDT - 4 months ago

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Mar 6, 2025, 12:48 PM EST - 6 months ago

Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:15 AM EST - 6 months ago

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 7:00 AM EST - 6 months ago

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Feb 20, 2025, 7:00 AM EST - 6 months ago

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Feb 13, 2025, 8:00 AM EST - 6 months ago

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Nov 21, 2024, 1:46 PM EST - 9 months ago

Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript

Nov 21, 2024, 7:30 AM EST - 9 months ago

Evogene Reports Third Quarter 2024 Financial Results

Nov 19, 2024, 7:00 AM EST - 9 months ago

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Nov 12, 2024, 7:00 AM EST - 10 months ago

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Nov 7, 2024, 7:00 AM EST - 10 months ago

Evogene Schedules Third Quarter 2024 Financial Results Release

Oct 31, 2024, 8:00 AM EDT - 10 months ago

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Oct 29, 2024, 8:00 AM EDT - 10 months ago

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Oct 8, 2024, 7:00 AM EDT - 11 months ago

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Aug 23, 2024, 8:55 AM EDT - 1 year ago

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Aug 22, 2024, 5:42 PM EDT - 1 year ago

Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Evogene Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 7:11 AM EDT - 1 year ago

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Evogene Schedules Second Quarter 2024 Financial Results Release

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil

Jul 23, 2024, 8:48 AM EDT - 1 year ago

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split

Jul 17, 2024, 8:00 AM EDT - 1 year ago

ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants

ICL

Jul 2, 2024, 7:00 AM EDT - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country

May 23, 2024, 4:57 PM EDT - 1 year ago

Evogene Ltd. (EVGN) Q1 2024 Earnings Call Transcript

$Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma$

May 23, 2024, 11:00 AM EDT - 1 year ago

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

May 23, 2024, 7:00 AM EDT - 1 year ago

Evogene Reports First Quarter 2024 Financial Results

May 21, 2024, 7:03 AM EDT - 1 year ago

Casterra Announces Additional Agreements with Seed Producers to Meet Existing & Growing Demand for its Elite Castor Seeds

May 9, 2024, 7:00 AM EDT - 1 year ago

Evogene Schedules First Quarter 2024 Financial Results Release

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Evogene Announces Filing of Annual Report on Form 20-F

Mar 20, 2024, 9:00 AM EDT - 1 year ago

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Mar 19, 2024, 9:00 AM EDT - 1 year ago

Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing

Mar 13, 2024, 9:00 AM EDT - 1 year ago

Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America

Mar 7, 2024, 1:35 PM EST - 1 year ago

Evogene Ltd. (EVGN) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 7:00 AM EST - 1 year ago

Evogene Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 6, 2024, 7:00 AM EST - 1 year ago

AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides

CTVA

Mar 5, 2024, 7:00 AM EST - 1 year ago

Casterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed Varieties

dukenuke Aug. 21 at 9:07 PM

2 · Reply

gekkooo Aug. 20 at 7:57 AM

0 · Reply

WilliamAnastasiades488 Aug. 18 at 2:46 PM

$EVGN is working on unique biotech applications, but progress is slow. KLTO’s ability to fast-track with AAVone looks like a smarter approach.

0 · Reply

mangingriskandcandles Aug. 5 at 8:27 PM

$EVGN I am ready for it to go up another 100%

0 · Reply

dukenuke Aug. 5 at 7:50 PM

$EVGN well this is highly unusual

0 · Reply

omenkes Jul. 30 at 11:37 AM

1 · Reply

dukenuke Jul. 29 at 3:11 PM

$EVGN Casterra new website: https://casterra.co/

1 · Reply

SmartBetting Jul. 24 at 12:19 PM

$EVGN goodluck.

0 · Reply

watcher64 Jul. 19 at 1:38 PM

$EVGN Gonna start adding more of this on Monday. At this price, the upside far outstrips the risk.

1 · Reply

dukenuke Jul. 16 at 2:43 AM

$EVGN anybody heard anything from Casterra lately? They seem to have gone dark.

1 · Reply

SkinnyDude911 Jul. 15 at 12:37 PM

$EVGN If they monetize the tech its a winner. Could be revolutionary. Anit of a no news bleed since the last press release. But the story is better than it was when it spiked over 2 .

1 · Reply

YFZ450 Jul. 15 at 12:58 AM

$EVGN next prediction below one and one last massive RS than BK... bio 101

0 · Reply

cupcakes4jesus Jul. 13 at 12:06 AM

$EVGN can someone catch me up to speed on this name? Is it a good buy? I just discovered it today, but it looks kinda interesting.

2 · Reply

aktienboersen Jul. 9 at 5:22 PM

$EVGN New Frontiers in AI-Driven Drug Discovery - Merging the power of science and AI to explore novel molecular spaces https://x.com/aktienboersen/status/1942988710733299949

1 · Reply

Strikeeeee Jul. 8 at 11:52 AM

$EVGN https://www.stocktitan.net/news/EVGN/evogene-announces-completion-of-transaction-for-the-sale-of-lavie-d47hsbl140ra.html 10$ run

1 · Reply

Strikeeeee Jul. 8 at 11:08 AM

$EVGN

0 · Reply

Strikeeeee Jul. 8 at 11:07 AM

$EVGN https://finviz.com/news/97595/evogene-announces-completion-of-transaction-for-the-sale-of-lavie-bios-activity-to-icl

0 · Reply

Rage_Against_The_Machine Jul. 8 at 11:06 AM

Evogene $EVGN completes strategic divestiture of Lavie Bio to ICL, transferring key AI assets. While this streamlines operations per their 'unlock value' strategy, the real question remains: Can their remaining subsidiaries deliver where Lavie couldn't? Retained partnership rights offer glimmer of future revenue potential. https://www.prnewswire.com/news-releases/evogene-announces-completion-of-transaction-for-the-sale-of-lavie-bios-activity-to-icl-302499902.html

0 · Reply

mangingriskandcandles Jul. 7 at 2:28 PM

$SYTA $FARM $EVGN

0 · Reply

goandgo Jul. 6 at 3:37 AM

$EVGN big holders sold their all shares last month and there is no catalysts here. hopeless

1 · Reply

SkinnyDude911 Jul. 4 at 1:44 PM

$EVGN only a matter of time.

0 · Reply

Disrupter Jul. 4 at 4:40 AM

$EVGN traders missed the recent memo. $10+

0 · Reply

Market Cap	7.00M
Revenue (ttm)	8.51M
Net Income (ttm)	-16.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-193.77%
Debt to Equity Ratio	0.00

Volume	16,800
Avg Vol	161,388
Day's Range	N/A - N/A
Shares Out	5.37M
Stochastic %K	51%
Beta	1.59
Analysts	Strong Sell
Price Target	$3.50